Accès gratuit
Volume 24, Numéro 4, Juillet 2015
Quid des patients spécifiques ?
Page(s) 424 - 432
Section Mise Au Point / Update
Publié en ligne 29 mai 2015
  • Louis DN, Ohgaki H, Wiestler OD, et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 114:97–109 [CrossRef] [PubMed] [Google Scholar]
  • Ostrom QT, Gittleman H, Farah P, et al (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1–56 [CrossRef] [PubMed] [Google Scholar]
  • Ricard D, Idbaih A, Ducray F, et al (2012) Primary brain tumours in adults. Lancet 379:1984–96 [CrossRef] [PubMed] [Google Scholar]
  • No authors listed] (1999) Guidelines for intensive care unit admission, discharge, and triage. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 27:633–8 [CrossRef] [PubMed] [Google Scholar]
  • Stupp R, Mason WP, van den Bent MJ, et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96 [CrossRef] [PubMed] [Google Scholar]
  • Stupp R, Hegi ME, Mason WP, et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 10:459–66 [CrossRef] [PubMed] [Google Scholar]
  • Hegi ME, Diserens AC, Gorlia T, et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003 [CrossRef] [PubMed] [Google Scholar]
  • van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al (2013) MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 19:5513–22 [CrossRef] [PubMed] [Google Scholar]
  • Cairncross G, Wang M, Shaw E, et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 31:337–43 [CrossRef] [PubMed] [Google Scholar]
  • Kostakou E, Rovina N, Kyriakopoulou M, et al (2014) Critically ill cancer patient in intensive care unit: Issues that arise. J Crit Care S0883-9441:00145–2 [Google Scholar]
  • Azoulay E, Soares M, Darmon M, et al (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1:5 [CrossRef] [PubMed] [Google Scholar]
  • Peigne V, Rusinová K, Karlin L, et al (2009) Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med 35:512–8 [CrossRef] [PubMed] [Google Scholar]
  • Legriel S, Marijon H, Darmon M, et al (2010) Central neurological complications in critically ill patients with malignancies. Intensive Care Med 36:232–40 [CrossRef] [PubMed] [Google Scholar]
  • Johnson DR, Brown PD, Galanis E, Hammack JE (2012) Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J Neurooncol 108:187–93 [CrossRef] [PubMed] [Google Scholar]
  • Bautista F, Paci A, Minard-Colin V, et al (2014) Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 61:1101–3 [CrossRef] [PubMed] [Google Scholar]
  • Skrypek M, Foreman N, Guillaume D, Moertel C (2014) Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer 61:2099–100 [CrossRef] [PubMed] [Google Scholar]
  • Pignatti F, van den Bent M, Curran D, et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–84 [CrossRef] [PubMed] [Google Scholar]
  • Soffietti R, Baumert BG, Bello L, et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–33 [CrossRef] [PubMed] [Google Scholar]
  • Daniels TB, Brown PD, Felten SJ, et al (2011) Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 81:218–24 [CrossRef] [PubMed] [Google Scholar]
  • Mandonnet E, Delattre JY, Tanguy ML, et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003 53:524–8 [Google Scholar]
  • Rigau V, Zouaoui S, Mathieu-Daudé H, et al (2011) French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 21:633–44 [CrossRef] [PubMed] [Google Scholar]
  • Houillier C, Wang X, Kaloshi G, et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–6 [CrossRef] [PubMed] [Google Scholar]
  • Everhard S, Tost J, El Abdalaoui H, et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11:348–56 [CrossRef] [PubMed] [Google Scholar]
  • Gorlia T, Delattre JY, Brandes AA, et al (2013) New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 49:3477–85 [CrossRef] [PubMed] [Google Scholar]
  • Panageas KS, Reiner AS, Iwamoto FM, et al (2014) Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol 16:1541–6 [CrossRef] [PubMed] [Google Scholar]
  • Stupp R, Reni M, Gatta G, et al (2007) Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63:72–80 [CrossRef] [PubMed] [Google Scholar]
  • van den Bent MJ, Brandes AA, Taphoorn MJ, et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–50 [CrossRef] [PubMed] [Google Scholar]
  • Cairncross JG, Wang M, Jenkins RB, et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–90 [CrossRef] [PubMed] [Google Scholar]
  • Li J, Wang M, Won M, et al (2011) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623–30 [CrossRef] [PubMed] [Google Scholar]
  • Esteller M, Garcia-Foncillas J, Andion E, et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–4 [CrossRef] [PubMed] [Google Scholar]
  • Tabouret E, Chinot O, Sanson M, et al (2014) Predictive biomarkers investigated in glioblastoma. Expert Rev Mol Diagn 14:883–93 [CrossRef] [PubMed] [Google Scholar]
  • Korfel A, Schlegel U (2013) Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9:317–27 [CrossRef] [PubMed] [Google Scholar]
  • Sierra del Rio M, Rousseau A, Soussain C, et al (2009) CNS lymphoma in immunocompetent patients. Oncologist 14:526–39 [CrossRef] [PubMed] [Google Scholar]
  • Abrey LE, Ben-Porat L, Panageas KS, et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5 [CrossRef] [PubMed] [Google Scholar]
  • Taal W, Oosterkamp HM, Walenkamp AM, et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–53 [CrossRef] [PubMed] [Google Scholar]
  • Gilbert MR, Dignam JJ, Armstrong TS, et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708 [CrossRef] [PubMed] [Google Scholar]
  • Chinot OL, Wick W, Mason W, et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–22 [CrossRef] [PubMed] [Google Scholar]
  • Taccone FS, Artigas AA, Sprung CL, et al (2009) Characteristics and outcomes of cancer patients in European ICUs. Crit Care 13:R15 [CrossRef] [PubMed] [Google Scholar]
  • Soares M, Salluh JI, Torres VB, et al (2005) Short- and long-term outcomes of critically ill patients with cancer and prolonged ICU length of stay. Chest 134:520–6 [CrossRef] [Google Scholar]
  • Cavaliere R, Farace E, Schiff D (2006) Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 63:1746–9 [CrossRef] [PubMed] [Google Scholar]
  • Ferlisi M, Shorvon S (2012) The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain J Neurol 135:2314–28 [CrossRef] [Google Scholar]
  • Kennedy J, Schuele SU (2013) Long-term monitoring of brain tumors: when is it necessary? Epilepsia 54 Suppl 9:50–5 [CrossRef] [Google Scholar]
  • Marcuse LV, Lancman G, Demopoulos A, Fields M (2014) Nonconvulsive status epilepticus in patients with brain tumors. Seizure 23:542–7 [CrossRef] [PubMed] [Google Scholar]
  • Schmiegelow K. (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146:489–503 [CrossRef] [PubMed] [Google Scholar]
  • Roch A, Wiramus S, Pauly V, et al (2011) Long-term outcome in medical patients aged 80 or over following admission to an intensive care unit. Crit Care 15:R36 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Azoulay E. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Curr Opin Oncol 21:318–26 [CrossRef] [PubMed] [Google Scholar]
  • Boussat S, El’rini T, Dubiez A, et al (2000) Predictive factors of death in primary lung cancer patients on admission to the intensive care unit. Intensive Care Med 26:1811–6 [CrossRef] [PubMed] [Google Scholar]
  • Kopterides P, Liberopoulos P, Ilias I, et al (2011) General prognostic scores in outcome prediction for cancer patients admitted to the intensive care unit. Am J Crit Care 20:56–66 [CrossRef] [PubMed] [Google Scholar]
  • Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. (2014) Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care 29:618–26 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Thiery G, Ciroldi M, et al (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–93 [CrossRef] [PubMed] [Google Scholar]
  • Thiéry G, Azoulay E, Darmon M, et al (2005) Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 23:4406–13 [CrossRef] [PubMed] [Google Scholar]
  • Lecuyer L, Chevret S, Thiery G, et al (2007) The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 2007 35:808–14 [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.